Fulcrum Therapeutics (FULC) Operating Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Operating Expenses for 9 consecutive years, with $29.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Expenses rose 47.92% year-over-year to $29.3 million; the TTM figure through Jun 2026 stood at $96.0 million (up 13.3% YoY), while the FY2025 annual figure was $84.8 million, down 16.81% from the prior year.
• Operating Expenses advanced to $29.3 million in Q2 2026 per FULC's latest filing, from $22.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $36.1 million in Q2 2022 and bottomed at $19.4 million in Q4 2024.
• Historically, Operating Expenses has averaged $26.1 million across 5 years, with a median of $27.8 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 50.09% — and 2024, when it slumped 32.69%.
• Fulcrum Therapeutics' Operating Expenses stood at $28.7 million in 2022, then rose by 0.72% to $28.9 million in 2023, then tumbled by 32.69% to $19.4 million in 2024, then gained by 16.8% to $22.7 million in 2025, then increased by 29.16% to $29.3 million in 2026.
• Business Quant data shows FULC's Operating Expenses at $29.3 million in Q2 2026, $22.2 million in Q1 2026, and $22.7 million in Q4 2025.